Resources
71 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/23/2023 (updated 5/24/2024)
Using data from 77 harm reduction programs in 25 US states, researchers found that 12-15% of powder methamphetamine and powder cocaine also contained fentanyl although the prevalence varied geographically. Prevalence of fentanyl in crystal methamphetamine and crack cocaine was lower. Heroin and xylazine were also found in unregulated stimulants. Xylazine reduced the ability to detect fentanyl.
Posted 5/17/2021 (updated 4/10/2024)
New medications for office-based treatment of opioid
addiction are comparable in efficacy to other chronic
conditions such as diabetes, asthma, and hypertension
when combined with other interventions and as part of a
comprehensive care plan. They are safe, highly effective,
can be prescribed and/or administered at the Community
Health Center, with a sustainable business plan.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 3/10/2021 (updated 4/5/2024)
There are safe ways to dispose of syringes you find on the ground. Sharing injection drug equipment can transmit infections, but there is little risk to someone who is accidentally poked or scratched by a discarded syringe.
Below you'll find information on how to pick them up, where to drop them off, and ways to get involved in cleaning up your neighborhood.
Posted 2/18/2021 (updated 4/4/2024)
Opioid use disorder (OUD), a chronic disease, is a major public health problem. Despite availability of effective treatment, too few people receive it and treatment retention is low. Understanding barriers and facilitators of treatment access and retention is needed to improve outcomes for people with OUD.
In this study we sought to assess 3-month outcomes from a patient-centered practice that included MAT with buprenorphine or naltrexone plus the option to participate in psychosocial treatments. The psychosocial treatments included case management, psychotherapy, peer recovery groups such as Narcotics Anonymous or Smart Recovery, or peer support through a local harm reduction program.
Posted 1/27/2021 (updated 4/4/2024)
The current study examined the accuracy of sensory discernment strategies by measuring study participants’ descriptions of the last opioid injected and checked with a fentanyl test strip (FTS) by that test's positive/negative result. The primary objective was to determine associations between FTS results and descriptions of the illi it opioid's physical appearance and physiological effects.
Posted 1/12/2021 (updated 4/4/2024)
This handbook is for anyone looking for help or information, and for people who care about them, who may be: Misusing prescription pain medications, using narcotics, heroin, or other opioid drugs; thinking about seeking help for an opioid problem; or Considering medications that help with recovery from opioid use disorder.
Posted 12/29/2020 (updated 4/4/2024)
An analysis of emergency department data shows a rise in nonfatal drug overdoses for youth under 15, from 2016 to 2019. Overdoses among the youngest kids aged 0-14 are relatively rate. However, risk increases with age, as the rate of all drug overdoses among youth aged 15-24 was more than double that of 11-14-year olds. Stimulant overdoses increased for all age groups, while heroin decreased for 15-24-year olds.
Posted 12/29/2020 (updated 4/4/2024)
Whereas outpatient treatment with medication for opioid use disorder (MOUD) is evidence based, there is a large network of inpatient facilities in the US that are reimbursed by commercial insurers and do not typically offer MOUD. This study is a comparison of rates of overdose and hospitalization after initiation of medication for Opioid Use Disorder in the inpatient vs outpatient setting.